Rare Daily Staff
Enzyvant said it has named Rachelle Jacques, former senior vice president and global franchise head of complement for Alexion, as its CEO.
Jacques replaces Alvin Shih, who led the wholly-owned subsidiary of Roivant Sciences since November 2016, shortly after the company’s founding. Shih will continue to be an advisor to the company.
Prior to working for Alexion, Jacques was vice president of U.S. Hematology Marketing at Shire and Baxalta and vice president of business operations for the global bioscience business unit at Baxter International.
“Rachelle is a proven leader and operator with deep experience bringing valued medicines to market in complex, fast-moving business environments,” said Myrtle Potter, Vant Operating Chair at Roivant Pharma and chair of Enzyvant’s board of directors. “We are thrilled that Rachelle is joining Enzyvant as the company prepares for the potential commercialization of Enzyvant’s first therapy.”
Enzyvant is currently in the process of completing a rolling biologics license application submission with the FDA for RVT-802, an investigational tissue-based therapy for the treatment of primary immunodeficiency associated with congenital athymia.
Enzyvant is also preparing to initiate a clinical trial of RVT-801, an investigational enzyme replacement therapy for the treatment of Farber disease.
“The company has made great strides since it was founded in 2016,” said Jacques. “I’m excited to build on that foundation as we enter this next phase of growth.”